PARP Inhibitor Biomarkers Market
完整報告名稱與涵蓋範圍
PARP Inhibitor Biomarkers Market Size, Share & Trends Analysis Report By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others), By Region, And By Segment Forecasts, 2024-2031.
報告摘要
The worldwide PARP Inhibitor Biomarkers Market stood at USD 897.8 Mn in 2023, and is anticipated to reach USD 1,751.6 Mn by 2031, recording a CAGR of 8.8% from 2024 through 2031.
PARP Inhibitor Biomarkers covers These biomarkers play a critical role in informing treatment decisions and identifying patients who are at the highest risk of benefiting from PARP inhibitor therapy. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the surging emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region anticipated to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PARP Inhibitor Biomarkers Market Snapshot
Chapter 4. Global PARP Inhibitor Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
5.2.1. Kits
5.2.2. Assays
Chapter 6. Market Segmentation 2: by Services Estimates & Trend Analysis
6.1. by Services & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Services:
6.2.1. BRCA 1&2 Testing
6.2.2. HRD Testing
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Breast Cancer
7.2.2. Ovarian Cancer
7.2.3. Others
Chapter 8. PARP Inhibitor Biomarkers Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.1.2. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.1.3. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.1.4. North America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.2.2. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.2.3. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.2.4. Europe PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.3.2. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.3.3. Asia-Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.3.4. Asia Pacific PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.4.2. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.4.3. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.4.4. Latin America PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Product, 2019-2031
8.5.2. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Services, 2019-2031
8.5.3. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.5.4. Middle East & Africa PARP Inhibitor Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Myriad Genetics, Inc.
9.2.2. Ambry Genetics
9.2.3. Thermo Fisher Scientific, Inc.
9.2.4. Illumina, Inc.
9.2.5. CENTOGENE N.V.
9.2.6. Amoy Diagnostics Co., Ltd.
9.2.7. Invitae Corporation
9.2.8. NeoGenomics Laboratories.
9.2.9. QIAGEN
9.2.10. Agilent Technologies, Inc.
9.2.11. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們